VANCOUVER, October 5, 2010 /PRNewswire/ -- Sirius Genomics, a developer of companion diagnostics, announced today that it has signed its second Contribution Agreement with the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP).

This research funding will be applied to discovery of genomic biomarkers that are predictive of patient response to therapeutics used in critical care medicine leading to improved disease outcomes.

Chris Wagner, President and CEO of Sirius Genomics, comments, NRC-IRAP's continued support reflects the Canadian Government's commitment to scientific innovation and support for the growth of Canadian companies. Funding from NRC-IRAP will help us advance our pipeline of companion diagnostics.

About Sirius Genomics:

Sirius Genomics develops companion diagnostics (CDx) that are closely tied to therapeutic decisions, leading to better patient outcomes through personalized medicine. Sirius generates value by improving the safety and effectiveness of pharmaceutical compounds. The Company correlates patient genetics with clinical outcomes, leading to proprietary and commercially viable CDx products that enable better drug treatment. The Company's first product is a genetic predictor of response to treatment for sepsis, a severe blood infection.

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.

For further information: Kamran Alam, Senior Director, Business Development, Sirius Genomics, +1-604-484-7195,

SOURCE: Sirius Genomics Inc.

CONTACT: For further information: Kamran Alam, Senior Director, BusinessDevelopment, Sirius Genomics, +1-604-484-7195,